Quantcast
Home > Quotes > JNCE
x

Jounce Therapeutics, Inc. Common Stock (JNCE) Quote & Summary Data

JNCE 
$5.58
*  
0.25
4.29%
Get JNCE Alerts
*Delayed - data as of Oct. 19, 2018  -  Find a broker to begin trading JNCE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
13
Today's High / Low
$ 6.015 / $ 5.43
Share Volume
232,266
50 Day Avg. Daily Volume
279,282
Previous Close
$ 5.83
52 Week High / Low
$ 29.25 / $ 5.51
Market Cap
182,062,164
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.96
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.28

Intraday Chart

Shares Traded

Share Volume:
232,266
50 Day Avg. Daily Volume:
279,282

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.96

Trading Range

The current last sale of $5.58 is 1.27% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 6.015 $ 29.25
 Low: $ 5.43 $ 5.51

Company Description (as filed with the SEC)

We are a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. We have developed a suite of integrated technologies that comprise our Translational Science Platform, enabling us to comprehensively interrogate the cellular and molecular composition of tumors. By focusing on specific cell types, both immune and non-immune, within tumors, we can prioritize targets and then identify related biomarkers designed to match the right therapy to the right patient. Through this deep, scientific understanding of the tumor microenvironment, or TME, our goal is to effectively and efficiently identify and develop new cancer immunotherapies designed to benefit patients with tumors across the spectrum from highly inflamed, or "hot," to poorly inflamed, or "cold," and especially those not well served by current therapies.  ... More ...  


Risk Grade

Where does JNCE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.86
Open Date:
Oct. 19, 2018
Close Price:
$ 5.58
Close Date:
Oct. 19, 2018

Consensus Recommendation

Analyst Info